Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Pricing Debate Generic Drugs Private Payers

At US Generic Association Annual Meeting, Worries About Sustainability

  • Analysis

Executive Summary

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.

You may also be interested in...



For Novartis' Generic Advair, Another 18 Months Was Too Far Into The Unknown

Company did not kill its development program because of US FDA feedback, but the experience seems to be another lesson in the difficulty in gaining approval for complex generics.

Azar: International Regulatory Harmonization Will Create More Stable Generic Markets

HHS secretary tells AAM that "fundamental" changes require legislation, but "FDA and our peers are exploring new potential areas for alignment."

Azar: International Regulatory Harmonization Will Create More Stable Generic Markets

HHS secretary tells AAM that "fundamental" changes require legislation, but "FDA and our peers are exploring new potential areas for alignment."

Table

View full table

Related Content

Pink Sheet
Generics Bulletin

Topics

Tags:
Pricing Debate Generic Drugs Private Payers
UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By